Lilly rebased on R&D in 2009, then cut drug development to 6 years — a $791B payoff

By 2009 Eli Lilly was staring at its own obituary: Prozac, a quarter of revenue and a third of profits, had lost patent exclusivity, and the 'Years YZ' put four more drugs — half of sales — into generic competition with no launches behind them. Then-CEO John Lechleiter rejected the industry's favorite escapes, M&A or selling a unit, and took a rebase to investors instead: 'We're going to stop growing earnings; we're going to shrink them... and we want you to stick with us and ride it out.' The stock traded at $28, and insiders recall the question: 'Is this actually a running concern?'

Then came the overhaul. Lilly's scientists averaged 11 years from clinic to market against an industry norm of eight, with five straight late-stage pipeline failures at one point. Under CEO Dave Ricks (2017) and chief scientific officer Dan Skovronsky, the company mapped all 800 steps of drug development, prioritized saving time over saving money, gave scientists 'permission to fail', and recruited trial participants directly — outfitting recreational vehicles as mobile labs rather than waiting on hospital enrollment.

Tirzepatide — spotted in a 12-person Singapore study whose participants dropped out because they lost so much weight — went from clinic to market in six years, and in 2020 Lilly produced the first COVID antibody therapy in eight months. The payoff: a $791 billion market cap that made Lilly the world's ninth-most-valuable company, worth more than Tesla or Exxon Mobil; 2023 sales of $34.1 billion, up 20%; and $7.3 billion of combined Mounjaro-Zepbound sales even with both on the FDA shortage list — tirzepatide patients lose on average 18% of body weight.

Lilly is spending $18 billion on plants since 2020 to chase demand, and Ricks has opened a second front: LillyDirect, an online pharmacy soft-launched in early 2023 that now sells Zepbound, Mounjaro and a migraine drug direct at half-off coupon rates — logistically messy and reviewed poorly on Reddit, but 'hugely successful' in the CEO's words.

Market cap $791 billion (ninth worldwide); 2023 sales $34.1B (+20%); Mounjaro and Zepbound $7.3B together despite shortages; stock $28 to $832.

The patent cliff hit half the portfolio at once, so buying growth would only delay the reckoning; only internally developed drugs could refill it.

Telling investors earnings would shrink bought the freedom to fund decade-long science instead of managing to quarterly EPS.

Reworking the 800-step development process attacked the real bottleneck — Lilly's own slowness — and the late-stage failures taught better study design.

The company stayed on hard, unglamorous targets like diabetes and Alzheimer's while rivals chased the immunotherapy boom; tirzepatide and donanemab proved the patience paid.

When patents expire, the bravest message to investors is 'earnings will shrink' — a rebase on internal R&D can beat the sector's favorite shortcut of buying growth.

Shortages are now the binding constraint: both tirzepatide brands sit on the FDA shortage list while the $18 billion plant build-out since 2020 takes three to four years per facility. LillyDirect has scaled despite cold-chain and state licensing hurdles. Ricks frames the July 2024 approval of donanemab (Kisunla, about $32,000 a year) — the product of a 35-year, $8 billion Alzheimer's effort — as evidence that the rebased R&D machine now delivers.